mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma

Apitoria Pharma appoints Dr. Sanjay Chaturvedi as CEO

Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023

Approx 800 million Indians do not have health coverage, says Expert

Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand

AnaBios acquires Cell Systems to expand human cell portfolio for drug discovery

Bridgewest Group launches new sterile injectable CDMO NovaCina

Microbion gets US patent for the use of inhaled pravibismane for pulmonary infections

Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039

FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients

Antibody-drug conjugates gain traction in China oncology market, says GlobalData

China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets

GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme

SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties

EIP Pharma and Diffusion Pharmaceuticals inks agreement to create CNS-focused company

EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging